Nasdaq · CIK 0001790340
IMRX Immuneering Corp
Insider trading from SEC Form 4. Last filing Jun 24, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Immuneering Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Harold Eugene Brakewood Chief Business Officer buy | $4,804 1,900 shares | +49% | - |
Transactions
The last 14 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | Harold Eugene Brakewood Chief Business Officer | POpen-market purchase Class A Common Stock | +1,900 | $2.53 | $4,804 | 5,800 | Jun 24, 2025 |
| Jun 13, 2025 | Ann E Berman director | AGrant or award Stock Optionderivative | +33,350 | $0.00 | $0 | 33,350 | Jun 16, 2025 |
| Jun 13, 2025 | Robert J Carpenter director | AGrant or award Stock Optionderivative | +33,350 | $0.00 | $0 | 33,350 | Jun 16, 2025 |
| Mar 21, 2025 | Igor Matushansky Chief Medical Officer | AGrant or award Stock Optionderivative | +118,000 | $0.00 | $0 | 118,000 | Mar 24, 2025 |
| Feb 5, 2025 | Michael Bookman CHIEF LEGAL OFFICER, SECRETARY | AGrant or award Stock Optionderivative | +110,000 | $0.00 | $0 | 110,000 | Feb 7, 2025 |
| Feb 5, 2025 | Harold Eugene Brakewood Chief Business Officer | AGrant or award Stock Optionderivative | +100,000 | $0.00 | $0 | 100,000 | Feb 7, 2025 |
| Feb 5, 2025 | Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | AGrant or award Stock Optionderivative | +240,000 | $0.00 | $0 | 240,000 | Feb 7, 2025 |
| Feb 5, 2025 | Benjamin J. Zeskind PRESIDENT AND CEO | AGrant or award Stock Optionderivative | +480,000 | $0.00 | $0 | 480,000 | Feb 7, 2025 |
| Feb 5, 2025 | Leah R Neufeld CHIEF PEOPLE OFFICER | AGrant or award Stock Optionderivative | +110,000 | $0.00 | $0 | 110,000 | Feb 7, 2025 |
| Feb 5, 2025 | Mallory Morales Chief Accounting Officer | AGrant or award Stock Optionderivative | +110,000 | $0.00 | $0 | 110,000 | Feb 7, 2025 |
| Jan 1, 2025 | Ann E Berman director | AGrant or award Stock Optionderivative | +23,485 | $0.00 | $0 | 23,485 | Jan 2, 2025 |
| Jan 1, 2025 | Peter Feinberg director | AGrant or award Stock Optionderivative | +23,485 | $0.00 | $0 | 23,485 | Jan 2, 2025 |
| Jan 1, 2025 | Laurie Keating director | AGrant or award Stock Optionderivative | +23,485 | $0.00 | $0 | 23,485 | Jan 2, 2025 |
| Jan 1, 2025 | Ann E Berman director | AGrant or award Stock Optionderivative | +17,614 | $0.00 | $0 | 17,614 | Jan 2, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Ann E Bermandirector
- Michael BookmanCHIEF LEGAL OFFICER, SECRETARY
- Harold Eugene BrakewoodChief Business Officer
- Robert J Carpenterdirector
- Peter Feinbergdirector
- Brett Matthew HallCHIEF SCIENTIFIC OFFICER
- Laurie Keatingdirector
- Igor MatushanskyChief Medical Officer
- Mallory MoralesChief Accounting Officer
- Leah R NeufeldCHIEF PEOPLE OFFICER
- Benjamin J. ZeskindPRESIDENT AND CEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.